Drug Fix: Could Other Products Use Peptide Order For Access, Industry Opposes CRL Release

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs consider the impact of the Health and Human Services Department’s temporary order allowing compounding of unapproved peptides on the drug industry (1:58), including whether stakeholder could use the precedent to gain access to other products (4:05). They also analyze HHS’ dismissal of US Food and Drug Administration safety concerns (11:28). In addition, the group discusses the Pharmaceutical Research and Manufacturers of America’s opposition to releasing complete response letters and the future of legislative efforts to codify the practice (19:52).

More On These Topics From The Pink Sheet

HHS Peptide Policy Brushes Off US FDA Safety Concerns As Hypothetical:
insights.citeline.com/pink-sheet/compliance/ma…

Peptides Compounding Would ‘Undermine’ US FDA Drug Approval Process, Ex-Agency Official Argues: insights.citeline.com/pink-sheet/pathways-and-…

US FDA’s Complete Response Letter Postings A Gift To Chinese Competitors, PhRMA Says:
insights.citeline.com/pink-sheet/product-revie…